congress - rete oncologica piemonte · congress advanced program milan 2010 advanced program 35th...

Advanced programcongress

Milan 2010

Advanced Program

35th ESMO CongressMilan, Italy8 – 12 October 2010

For frequent updates please visit www.esmo.org

congress

Milan 2010

2 35th ESMO Congress · Milan, Italy · 8–12 October 2010

congress

Milan 2010

Congress offi cers

ESMO and Congress PresidentDavid J. Kerr, Oxford, GB and Doha, Qatar

35th ESMO Congress Scientifi c CommitteeEx-offi cio membersRolf A. Stahel, Zurich, Switzerland, Chair David J. Kerr, Oxford, GB and Doha, QatarAndrés Cervantes, Valencia, SpainFortunato Ciardiello, Naples, Italy Basic science and translational research Marco A. Pierotti, Milan, Italy, ChairMartin Fey, Bern, Switzerland Carlos Caldas, Cambridge, GB Maria Grazia Daidone, Milan, Italy Miguel A. Piris, Madrid, SpainJacques Pouyssegur, Nice, France

Breast cancerLuca Gianni, Milan, Italy, ChairJohn Crown, Dublin, Ireland Michele De Laurentiis, Naples, Italy Wolfgang Eiermann, Munich, Germany Christopher Poole, Warwick, GBChristoph Zielinski, Vienna, Austria

Chest tumors Jean-Charles Soria, Villejuif, France, ChairDavid Gandara, Sacramento, USA Cesare Gridelli, Avellino, ItalyLuis Paz-Ares, Madrid, SpainRobert Pirker, Vienna, AustriaNajahiro Saijo, Tokyo, JapanDavid Waller, Leicester, GB

Developmental therapeutics Johann S. de Bono, Sutton, GB, ChairMaja de Jonge, Rotterdam, The Netherlands Christian Dittrich, Vienna, AustriaManuel Hidalgo, Madrid, Spain Jan Schellens, Amsterdam, The Netherlands Anthony Tolcher, San Antonio, USA

Gastrointestinal tumors, including colorectal Jean-Yves Douillard, Nantes, France, Chair Eduardo Diaz-Rubio, Madrid, Spain Claus-Henning Koehne, Oldenburg, Germany Carmelo Pozzo, Rome, Italy Arnaud Roth, Geneva, SwitzerlandAlberto Sobrero, Genoa, Italy

Genitourinary tumors Carsten Bokemeyer, Hamburg, Germany, Chair Maria de Santis, Vienna, AustriaTim Eisen, Sutton, GBKarim Fizazi, Villejuif, France Vesa Kataja, Kuopio, FinlandThomas Powles, London, GB

Gynecological cancers Jonathan Ledermann, London, GB, ChairJames Brenton, Cambridge, GB Andrés Cervantes, Valencia, Spain Angiolo Gadducci, Pisa, ItalyStan Kaye, Sutton, GBAte van der Zee, Groningen, The Netherlands

Head and neck cancer Lisa Licitra, Milan, Italy, ChairVincent Gregoire, Brussels, Belgium Jean Louis Lefebvre, Lille, France Marshall Posner, Boston, USAAmanda Psyrri, Athens, GreeceMartin Schlumberger, Villejuif, France

Hematological malignancies and myeloma Michele Ghielmini, Bellinzona, Switzerland, Chair Martin Dreyling, Germany Jean-Luc Harousseau, Nantes, FranceFrancesco Lo-Coco, Rome, ItalyMichael Pfreundschuh, Homburg, Germany Lena Specht, Copenhagen, Denmark

Oncology and public health Hans H. Storm, Copenhagen, Denmark, ChairDavid Brewster, Edinburgh, GB Lars Holmberg, London, GBHeinz Ludwig, Vienna, AustriaHans-Jörg Senn, St. Gallen, SwitzerlandAndres Ullrich, Geneva, Switzerland

Palliative and supportive care Jørn Herrstedt, Odense, Denmark, Chair J. Peter Donnelly, Nijmegen, The Netherlands Dorothy M.K. Keefe, Adelaide, AustraliaLukas Radbruch, Aachen, GermanyFausto Roila, Perugia, ItalySimon Van Belle, Ghent, Belgium

Sarcoma, melanoma and rare tumors Paolo G. Casali, Milan, Italy, ChairJean-Yves Blay, Lyon, FranceAlessandro Gronchi, Milan, Italy Axel Le Cesne, Villejuif, France Patrick Schöffski, Leuven, BelgiumPancras C. W. Hogendoorn, Leiden, The Netherlands

35th ESMO Congress Educational Steering CommitteeAndrés Cervantes, Valencia, Spain, ChairFortunato Ciardiello, Naples, ItalyMichael Cullen, Birmingham, GBMario A. Dicato, LuxembourgNicholas Pavlidis, Ioannina, GreeceDirk Schrijvers, Antwerp, BelgiumRolf A. Stahel, Zurich, Switzerland

35th ESMO Congress Local CommitteeUmberto Veronesi, Milan, Honorary ChairRoberto Labianca, Bergamo, Executive ChairFrancesco Boccardo, GenoaPaolo G. Casali, MilanFrancesco Cognetti, RomeFilippo De Braud, MilanFrancesco De Lorenzo, RomeSergio Dompé, MilanMarina Garassino, MilanCarmelo Iacono, RagusaGiovanni Rosti, Treviso

35th ESMO Congress · Milan, Italy · 8–12 October 2010 3

congress

Milan 2010

Presidential welcomeThe 35th ESMO Congress, 8–12 October 2010 will be a mag-netic meeting point for medical oncology specialists across Europe and the ideal forum to present and promote excel-lence in oncology. The European Society for Medical Oncology promises to bring together the best and brightest minds in the profession today, offering a Congress of the highest sci-entific quality.Being an oncologist today is just as challenging as it is re-warding. Oncology professionals are faced with heavy work-loads, pressure to perform and the need to be the best - clinician - researcher - practitioner; the need to build expertise and remain up-to-date; accumulate CME points, find financial aid and the need to publish. A time consuming and overwhelming job, but if done well can mean improving cancer care. Being the best means making smart choices and making the most of your time. The ESMO Congress is the answer to these challenges. The ESMO Congress is the right choice.The 2010 Congress will take place in Milan, a city with an impressive network of oncology organizations and professionals. ESMO has tapped into this network and is working in close collaboration with not only the local but also the international oncology community to offer a robust scientific program which meets the career needs of Congress attendees. The Congress features special Joint Symposia in collaboration with important international oncology organizations such as AIOM, ASCO, CSCO, ESSO, ESTRO, UICC and WHO.The Congress is also a time to reconnect and network with colleagues, to share expertise and enjoy both professional and personal interaction.

On behalf of ESMO, I invite you to join us at THEmeeting for medical oncologists, the 35th ESMOCongress.

Welcome from the Program ChairsOncology has entered into a period of radical progress with innovative new ways of combating cancer. Yet, in 2010 oncological diseases will replace cardiovascular diseases as the major cause of death. As oncology professionals, this is an implicit call to action. The 2010 ESMO Congress will strive to address this challenge with sessions present-ing personalized therapies, practice-changing studies and public health policy. The entry of targeted cancer therapies provides new treat-ment opportunities, but also raises new questions in daily clinical practice. The Congress covers the whole range of diseases and is organized into different session types that aim to answer - clinically very relevant questions. Beyond disease-oriented type tracks and topics that deal with com-ponents of translational research, the sessions are set up to trigger greater interaction with the audience by stimulating discussion among participants from different disciplines. Certain sessions will also cover the professional interest of medical oncologists in different stages of their careers. Despite major improvements in the therapeutic options available today, metastases remain a challenging clinical problem. As systemic therapies have improved, the role for ablative approaches to limit metastases is expanding. Different disciplines must work together more than ever before to tackle this challenge. The Congress will highlight major practice-changing data and provide a comprehensive overview of new advances in oncology.

We encourage you to join us in Milan and contribute to advancing the science of medical oncology.

David J. Kerr,ESMO and 35th ESMO Congress President

Left:Rolf A. Stahel, 35th ESMO Congress Scientific Chair

Right:Andrés Cervantes, 35th ESMO Congress Educational Chair

Invitation to the 35th ESMO Congress


congress

Milan 2010

Congress venueThe 35th ESMO Congress will take place at the Fiera Milano Congressi, located in the heart of the city.

Official languageThe official language of the Congress is English. Translation to other languages will not be available.

ParticipantsMore than 13,000 participants representing medical oncology and related specialties are expected to join this program.

Abstract submissionAbstract submission will be possible online only from Janu-ary 2010 until the deadline of 19 May 2010. Abstracts accepted for presentation during the Congress will be scheduled in the proffered paper, poster discussion and poster sessions. The best poster in each category will be recognized.

Late-breaking abstractsLate-breaking abstracts may be submitted for studies with new research findings for which no preliminary data are available at the time of the abstract submission deadline. A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline of 19 May 2010. Late-breaking abstracts accepted for presentation during the Congress will be scheduled in proffered paper sessions or the Presidential Symposium and published online only.

Travel grantsBased on the quality of submitted abstracts, travel grants will be available upon application for oncologists under the age of 40. Where requested, grants will be awarded by the 35th ESMO Congress Scientific Committee on a com-petitive basis to the best-scored abstracts submitted to the 35th ESMO Congress.

PublicationsArticles relating to the Educational and Challenge Your Expert sessions will be published in the Educational Book as a supplement of the official ESMO scientific journal, Annals of Oncology. Invited and accepted abstracts will be published in the Abstract Book, also a supplement of Annals of Oncology. Late-breaking abstracts will be pub-lished online only.

CME accreditationThe program of this event will be:• Accredited with ESMO-MORA category 1 points;• Submitted for CME accreditation to ACOE (Accredita-

tion Council for Oncology in Europe). ACOE accredita-tion has been endorsed by the Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). These credits are also recognized by the American Medical Association (AMA) as Physician’s Recognition Award (AMA PRA Category 1 credits).

• Submitted for Italian CME accreditation (crediti ECM).

Congress WebcastThe entire program of the 35th ESMO Congress will be Webcast. Access to the Congress Webcast will be restricted for the first 3 months following the Congress to ESMO members and non-ESMO members who elect to pay the additional Webcast fee; thereafter the Webcast will be freely available to everyone on the ESMO Website.

ESMO ExaminationEvery year ESMO offers an examination which is open to ESMO Full and Junior Members only. The certificate al-lows Members to participate in the ESMO Medical Oncolo-gist’s Recertification Approval (ESMO-MORA). During the Congress, the examination session will take place from 17.30 to 19.30 on Saturday, 9 October 2010. For further information, please contact the ESMO Examination Work-ing Group Coordinator ([email protected]) or visit www.esmo.org/education/certifi cation-and-accreditation/esmo-examination.html

Passport / visaA valid passport entitles EU and North American citizens to enter Italy. Citizens of other countries should check with a Italian diplomatic representative in their home country.

Official carrier

The Star Alliance™ Members Airlines are pleased to be appointed as the Official Airline Network for the 35th ESMO Congress, Milan, Italy, 8–12 October 2010. To obtain the Star Alliance™ Conventions Plus discounts, please call the reservation office of a participating Star Alliance Member Airline and quote the following Convention Code LH13S10. Registered participants plus one accompanying person travelling to the event are automatically granted a discount of up to 20%, depending on fare and class of travel booked.The participating airlines for this event are: Adria Airways, Air Canada, Air China, ANA, Asiana Airlines, Austrian Air-lines, bmi, Croatia Airlines, EgyptAir, LOT Polish Airlines, Lufthansa, Scandinavian Airlines, South African Airways, Spanair, SWISS International Air Lines, TAP Portugal, THAI, Turkish Airlines, United, US Airways.For booking office information please visit:www.staralliance.com/conventionsplus

Discounts are offered on published business and econo-my class fares, excluding Website / internet fares, senior and youth fares, group fares and Round the World fares.Please note: For travel from Japan and New Zealand spe-cial fares or discounts are offered by the participating air-lines on their own network.When making your travel plans please present con-firmation of your registration or proof of attendance.

TransportationPublic transportation for travel between the conference center and the official hotels booked through the official agency is offered to the registered participants.

congress General information

Official carrierOfficial carrier


congress

Milan 2010

InsuranceThe organizers bear no responsibility for untoward events in connection with, before, during and after the Congress. Participants are strongly advised to take out their own personal and travel insurance coverage.

AccommodationAccommodation in Milan is available in all hotel categories. Please see page 21 for further details.

ExhibitionThe major pharmaceutical companies active in the fi eld of oncology are expected to take part in the Congress as exhibitors.

Industry Satellite symposiaIndustry Satellite symposia will be inserted into the Congress program on Friday, 8 October 2010 between the hours of 09.00 and 18.30 and on Sunday 10 and Monday 11 October 2010 between the hours of 17.45 and 19.45. Details will be posted online on the ESMO Web site as soon as they become available.

Opening ceremonyParticipants attending the Congress are welcome to attend the official Opening ceremony on Friday, 8 October 2010, between 18.30 and 20.00 hours in the foyer of the congress center. The Opening ceremony is open to participants, ac-companying persons and exhibitors.

ESMO Foundation Benefit EventA benefit concert will be organized by the ESMOFoundation on Sunday evening, 10 October 2010 at the prestigious Teatro alla Scala. Tickets will be available for purchase online prior to the Congress and, if still available, on-site. Further details will be made available on the ESMO Website www.esmomilan2010.org

Special sessionAn ESMO/JSMO Joint Symposium will be held during the Congress. Details will be posted online as soon as the session is fi nalized.

Important deadlines19 May 2010Abstract submission

7 July 2010Early registration

4 August 2010Group registration, list of participant names

25 August 2010 Late-breaking abstracts

1 September 2010Late registration and pre-registration closure

General information



Milan 2010

Friday, 8 October 2010 14.00–17.00YO Masterclass: The importance of conductingwell-designed clinical trialsChairs: Susana Banerjee, London/GB andMarina Garassino, Milan/IT Session shooters: Raffaele Califano, Manchester/GBKonstantinos Kamposioras, Athens/GRChristophe Massard, Villejuif/FR

14.00 Statistical issues and how to use biomarkers as surrogates in the 21st century Marc Buyse, Ottignies, Louvain-la-Neuve/BE

14.50 Coffee break

15.10 Biobanking in clinical trials: What, when and how should I collect samples? Maria Grazia Daidone, Milan/IT

16.00 Break

16.10 Stopping a cancer trial early: Is it really for the benefit

of patients? What about the quality of data? Pinuccia Valagussa, Milan/IT 18.30–20.00Opening Ceremony

Saturday, 9 October 2010 08.00–08.45Young Oncologist BreakfastHow to write an outstanding manuscriptDavid J. Kerr, Doha/QA

08.00–09.00Challenge Your Expert sessionCancer of Unknown Primary site:20 questions to be answeredNicholas Pavlidis, Ioannina/GR

08.00–09.00Challenge Your Expert sessionMesotheliomaWalter Weder, Zurich/CH

08.00–09.00Challenge Your Expert sessionGenetic counselling for hereditary predisposition to ovarian and breast cancerJames Mackay, London/GB

08.00–09.00Challenge Your Expert sessionOsteosarcomaStefan Bielack, Stuttgart/DE

08.00–09.00Patient cases sessionHepatocellular carcinoma:A multi-step therapeutic approachChairs and Speakers: Jordi Bruix, Barcelona/ES andJean-Luc Raoul, Rennes/FR

08.00 An early stage HCC Jordi Bruix, Barcelona/ES

08.10 An intermediate case of HCC Jean-Luc Raoul, Rennes/FR 08.20 Discussion

08.00–09.00Patient cases session Team work in palliative careChairs and Speakers: Philip Larkin, Dublin/IE andLukas Radbruch, Aachen/DE

08.00 What nurses contribute Philip Larkin, Dublin/IE

08.10 What doctors contribute Lukas Radbruch, Aachen/DE 08.20 Discussion

08.00–09.00Multidisciplinary Interactive Session (MIS)Optimal integration of chemotherapy and radiotherapy insmall cell lung cancerChairs and Speakers: Corinne Faivre-Finn, Manchester/GBand Fiona Blackhall, Manchester/GB

08.00 Corinne Faivre-Finn, Manchester/GB

08.15 Fiona Blackhall, Manchester/GB

08.30 Discussion

09.00–10.30Educational sessionDiagnostic and management issues in metastaticbreast cancerCo-Chairs: José Baselga, Barcelona/ES andFabrice André, Villejuif/FR

09.00 What can the pathologist offer for optimal treatment choice?

Giuseppe Viale, Milan/IT

09.30 Treatment for triple negative breast cancer Fabrice André, Villejuif/FR

10.00 Treatment of Her2-overexpressing breast cancer José Baselga, Barcelona/ES



Milan 2010

09.00–10.30Educational sessionNew therapeutic opportunities in urological cancerChair: Joaquim Bellmunt, Barcelona/ESCo-Chair: Vesa Kataja, Kuopio/FI

09.00 New hormonal agents in the treatment of advanced prostate cancer Johann De Bono, Sutton/GB

09.30 New agents for bladder cancer Joaquim Bellmunt, Barcelona/ES

10.00 How to select targeted therapy in renal cancer Bernard Escudier, Villejuif/FR

09.00–10.30Educational sessionAdvances in neuroendocrine tumorsChair: William Travis, New York, NY/USCo-Chair: George Pentheroudakis, Kardamitsia/GR

09.00 Lung neuroendocrine William Travis, New York, NY/US

09.30 Gastrointestinal neuroendocrine tumors Kjell Oeberg, Uppsala/SE

10.00 Merkel tumors Jürgen Becker, Würzburg/DE 09.00–10.30Educational sessionHow much do we know about cancer cells? Chair: Carlos Cordon-Cardo, New York, NY/USCo-Chair: Marco A. Pierotti, Milan/IT

09.00 Epithelial-mesenchymal transition (EMT) phenomenon Pierre Savagner, Montpellier/FR

09.30 Cancer stem cells Carlos Cordon-Cardo, New York, NY/US

10.00 Circulating cancer cells Dimitris Mavroudis, Heraklion/GR 09.00–10.30ESMO/CSCO Joint SymposiumPersonalised medicine: Do ethnic differences matter?Chairs: David J. Kerr, Oxford/GB & Doha/QA andJin Li, Shanghai/CN

09.00 Pharmogenomic and SNP in diverse ethnicity Howard McLeod, Chapel Hill, NC/US

09.20 Hepatocellular carcinoma (HCC) Jin Li, Shanghai/CN

09.40 Personalized management of lung cancer: EGFR mutation and beyond Tony Mok, Hong Kong/CN

10.00 Colorectal cancer David J. Kerr, Oxford/GB & Doha/QA

10.20 Conclusions

09.30–10.30Multidisciplinary Interactive Session (MIS)Locally advanced pancreatic cancer Chairs and Speakers: Christophe Louvet, Paris/FR and Hanno Riess, Berlin/DE

09.30 Hanno Riess, Berlin/DE

09.45 Christophe Louvet, Paris/FR

10.00 Discussion 11.00–12.30Educational sessionTreatment of PT1N0 breast cancerChair: Angelo Di Leo, Prato/ITCo-Chair: Fatima Cardoso, Brussels/BE

11.00 Multigene predictors to assess risk of relapse Christos Sotiriou, Brussels/BE

11.30 Benefits and adverse effects of endocrine therapy Marco Colleoni, Milan/IT

12.00 Chemotherapy with or without trastuzumab Angelo Di Leo, Prato/IT 11.00–12.30Educational sessionAdvances in the treatment of advanced colorectal cancerChair: Claus-Henning Koehne, Oldenburg/DECo-Chair: Thierry André, Paris/FR

11.00 What can the molecular pathologist offer for optimal decision?

Philip Quirke, Leeds/GB

11.30 Chemotherapy: Which drugs and when? Alberto Sobrero, Genoa/IT

12.00 How to integrate molecular targeted agents in the continuum of care

Claus-Henning Koehne, Oldenburg/DE

11.00–12.30Educational sessionUpdates in B-cell malignanciesChairs: Michele Ghielmini, Bellinzona/CHCo-Chair: Håkan Mellstedt, Stockholm/SE

11.00 Multiple myeloma Meletios Dimopoulos, Athens/GR

11.30 Follicular lymphoma Michele Ghielmini, Bellinzona/CH

12.00 Chronic lymphocytic leukemia (CLL) Michael Hallek, Cologne/DE



Milan 2010

11.00–12.30Educational sessionPrevention and treatment of side effects ofsystemic treatmentChair: Mario Dicato, Luxembourg/LUCo-Chair: Jørn Herrstedt, Odense/DK

11.00 Anemia Mario Dicato, Luxembourg/LU

11.30 Cardiotoxicity Josep Tabernero, Barcelona/ES

12.00 Bone loss Jean-Jacques Body, Brussels/BE 11.00–12.30ESMO/ESTRO/ESSO Joint SymposiumSurgery, radiotherapy and ablation of metastaticdisease and chemotherapy for localized disease:Changing roles in multidisciplinary managementof colorectal cancerChairs: Jean Bourhis, Villejuif/FR andDavid J. Kerr, Oxford/GB & Doha/QA

11.00 Image guided therapy of metastases from colorectal cancer Thierry Debaere, Villejuif/FR

11.20 It’s resectable, but is it curable? Graeme Poston, Liverpool/GB

11.40 Radiotherapy: From palliation to cure and prophylaxis?

Guy Storme, Brussels/BE

12.00 Locoregional delivery of chemotherapy for metastatic CRC Rachel Midgley, Oxford/GB

12.20 Conclusions Peter Naredi, Umea/SE

12.45–13.35Keynote LecturePolymorphisms in drug metabolising enzymes anddrug transporters:Influence on drug pharmacokinetics andpatient response to treatmentChair: Marco A. Pierotti, Milan/IT Keynote Speaker: Jos Beijnen, Amsterdam/NL 14.15–15.45Educational sessionEarly-stage NSCLC: Challenges in staging andadjuvant treatment Chair: Thierry Le Chevalier, Villejuif/FRCo-Chair: Paul Baas, Amsterdam/NL

14.15 Evidence-based staging Johan Vansteenkiste, Leuven/BE

14.45 Adjuvant CT: Where is it going? Thierry Le Chevalier, Villejuif/FR

15.15 Do we have markers to select patients for adjuvant therapies? Giorgio Scagliotti, Orbassano/IT

14.15–15.45Educational sessionChallenging issues in ovarian cancerChair: Jonathan Ledermann, London/GBCo-Chair: Cristiana Sessa, Bellinzona/CH

14.15 How can proteomic profiling guide us in selecting therapy?

Elise Kohn, Bethesda, MD/US

14.45 The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer

Michael Bookman, Tucson, AZ/US

15.15 Optimal treatment for relapsing ovarian cancer Jonathan Ledermann, London/GB 14.15–15.45Educational session (repetition)Diagnostic and management issues in metastaticbreast cancer 14.15–15.45Educational session (repetition)Advances in neuroendocrine tumors

16.00–17.30Educational session (repetition)Advances in the treatment of advancedcolorectal cancer 16.00–17.30Educational session (repetition)Treatment of PT1N0 breast cancer 16.00–17.30Educational session (repetition)New therapeutic opportunities in urological cancer 16.00–17.30Educational session (repetition)How much do we know about cancer cells? 16.00–17.30Special sessionChronic Disease Alliance: A time to work across specialtiesESMO in association with the European Society ofCardiology, the European Respiratory Society and the European Association for the Study of Diabetes

17.30–19.30ESMO Examination 2010

Sunday, 10 October 2010

08.00–08.45Young Oncologist Breakfast How to conduct effective public speaking andslide presentationsJan Vermorken, Edegem/BE

08.00–09.00Challenge Your Expert session (repetition)Cancer of Unknown Primary site:20 questions to be answered



Milan 2010

08.00–09.00Challenge Your Expert session (repetition)Mesothelioma

08.00–09.00Challenge Your Expert session (repetition)Genetic counselling for hereditary predisposition to ovarian and breast cancer

08.00–09.00Challenge Your Expert session (repetition)Osteosarcoma

08.00–09.00Patient cases sessionChallenging cases in testicular cancerChairs and Speakers: Carsten Bokemeyer, Hamburg/DE andChristian Kollmannsberger, Vancouver/CA

08.00 Treatment options in early stage seminoma Christian Kollmannsberger, Vancouver/CA 08.10 Relapsed and/or refractory non-seminoma Carsten Bokemeyer, Hamburg/DE

08.20 Discussion

08.00–09.00Patient cases session How to improve curability of locally advanced head andneck cancerChairs and Speakers: Johannes Langendijk, Groningen/NL and Dirk Schrijvers, Antwerp/BE

08.00 Site-related co-morbidities in decision making Johannes Langendijk, Groningen/NL

08.10 Supportive care measures to improve patient outcome Dirk Schrijvers, Antwerp/BE

08.20 Discussion 09.00–10.30Educational session (repetition)Updates in B-cell malignancies 09.00–10.30Educational session (repetition)Early-stage NSCLC: Challenges in staging andadjuvant treatment

09.15–10.15Controversy sessionOver-diagnosis of breast cancer byscreening is a peril Moderator: Ian Smith, London/GB 09.15 Introduction and vote Ian Smith, London/GB

09.25 Contra Speaker – Benefit Harry De Koning, Rotterdam/NL

09.45 Pro Speaker – Peril Micheal Baum, London/GB

10.05 Conclusions and vote Ian Smith, London/GB 09.15–10.15Multidisciplinary Interactive Session (MIS)Locally advanced rectal cancerChairs and Speakers: Andrés Cervantes, Valencia/E and Cornelis van de Velde, Leiden/NL 09.15 Cornelis van de Velde, Leiden/NL

09.30 Andrés Cervantes, Valencia/ES

09.45 Discussion

09.30–11.00Special sessionCommunication skills training (CST)Chair: Alexander Kiss, Basel/CHCo-Chair: Friedrich Stiefel, Lausanne/CH 09.30 Introduction Alexander Kiss, Basel/CH

09.35 CST in oncology: Results from a consensus meeting among European experts in 2009

Friedrich Stiefel, Lausanne/CH

09.55 A reaction to the proposition of the European consensus on CST in oncology Darius Razavi, Brussels/BE

10.15 Mandatory training, minimal requirements and implementation of CST in oncology:

The European perspective Wolf Langewitz, Basel/CH

10.35 The future of CST in oncology Lesley Fallowfield, Brighton/GB

10.55 Conclusions Alexander Kiss, Basel/CH 10.45–12.15Special symposiumTargeted therapies in NSCLC:State-of-the-art and new developmentsChair: Luis Paz-Ares, Seville/ESCo-Chair: Rolf A. Stahel, Zurich/CH

10.45 Introduction Luis Paz-Ares, Seville/ES

10.50 Gefitinib – the resurrection Luis Paz-Ares, Seville/ES

11.05 Erlotinib – the adult Rafael Rosell, Badalona/ES

11.20 Bevacizumab – the adolescent Jean-Charles Soria, Villejuif/FR

11.35 Cetuximab – the newborn Ken O'Byrne, Dublin/IE



Milan 2010

11.50 New molecular targets – the next generation of drugs Cesare Gridelli, Avellino/IT

12.05 Conclusions Rolf A. Stahel, Zurich/CH 10.45–12.15Educational session (repetition)Challenging issues in ovarian cancer 10.45–12.45ESMO Clinical RecommendationsChair: Nicholas Pavlidis, Ioannina/GRCo-Chair: Andrés Cervantes, Valencia/ES

10.45 Introduction Nicholas Pavlidis, Ioannina/GR

10.50 ESMO Clinical Recommendations questionnaire Andrés Cervantes, Valencia/ES

10.55 Breast cancer (triple negative) Helen Gogas, Athens/GR

11.15 Discussant Andrew Tutt, London/GB

11.30 GIST Laura Kairevice, Kaunas/LT

11.50 Discussant Alessandro Gronchi, Milan/IT

12.05 Pancreatic cancer Stefan Boeck, Munich/DE

12.25 Discussant Stefano Cascinu, Ancona/IT

12.40 Conclusions Andrés Cervantes, Valencia/ES 11.00–12.30Educational session (repetition)Prevention and treatment of side effects of systemic treatment 11.00–12.30Special symposiumTargeting molecular pathways in the jungle of soft tissue sarcoma histologyChair: Eva Wardelmann, Bonn/DECo-Chair: Michael Montemurro, Lausanne/CH

11.00 Introduction Michael Montemurro, Lausanne/CH

11.05 Angiogenesis inhibitors: Are they useful for all sarcomas? Stefan Sleijfer, Rotterdam/NL

11.25 mTOR inhibitors: From lymphangioleiomyomatosis to where?

Paolo Casali, Milan/IT

11.45 Is the indication of IGFR antibodies in advanced refractory sarcomas expanding?

Jean-Yves Blay, Lyon/FR

12.05 At the crossroads of molecular pathways and sarcoma subtypes Jean-Michel Coindre, Bordeaux/FR

12.25 Conclusions Eva Wardelmann, Bonn/DE 12.30–13.20Keynote LectureA historical view and perspectives on angiongenesiinhibition and in particular anti-VEGF therapy in cancer Chair: Maria Grazia Daidone, Milan/IT Keynote Speaker: Peter Carmeliet, Leuven/BE 13.30–14.30Controversy sessionAnti-angiogenic agents should be used for the first-line treatment of ovarian cancerModerator: Jonathan Ledermann, London/GB

13.30 Introduction and vote Jonathan Ledermann, London/GB

13.40 Pro Speaker Nicoletta Colombo, Milan/IT

14.00 Contra Speaker Gordon Rustin, Northwood/GB

14.20 Conclusions and vote Jonathan Ledermann, London/GB 13.45–15.15Special symposiumBullseye: PARPChair: Johann de Bono, Sutton/GBCo-Chair: Hilary Calvert, Newcastle/GB

13.45 Introduction: From platinum to PARP Hilary Calvert, Newcastle/GB

13.50 Targeting the Achilles heel: Synthetic lethality Alan Ashworth, London/GB

14.10 Encouraging first experiences with PARP inhibitors Ruth Plummer, Newcastle/GB

14.30 Early tales: PARP and BRCA Jan H.M. Schellens, Amsterdam/NL

14.50 Later tales: Phase II and beyond Andrew Tutt, London/GB

15.10 Conclusions Johann de Bono, Sutton/GB



Milan 2010

13.45–15.15Educational sessionTowards an individualized approach of advancednon-small cell lung cancerChair: Enriqueta Felip, Barcelona/ESCo-Chair: Rafal Dziadziuszko, Gdansk/PL

13.45 Should we continue to use the term non-small cell lung cancer?

Adi F. Gazdar, Dallas, TX/US

14.15 How to integrate current knowledge in selecting first line therapy

Enriqueta Felip, Barcelona/ES

14.45 Consequences of targeted treatments for second line therapy

Federico Cappuzzo, Rozzano/IT 13.45–15.15Educational sessionAdvances in head and neck cancerChair: Jan Vermorken, Edegem/BECo-Chair: Marshall Posner, Boston, MA/US

13.45 The role of papilloma virus infection Maura Gillison, Columbus, OH/US

14.15 Integrating systemic agents into multimodality treatment of locally advanced diseases Marshall Posner, Boston, MA/US

14.45 Optimal treatment for relapsing or metastatic disease Jan Vermorken, Edegem/BE

14.45–16.15ESMO/AIOM Joint Symposium Young medical oncologists facing daily difficultiesin clinical practice Chairs: Michael Karamouzis, Papagou/GR andMassimo di Maio, Naples/IT

14.45 Introduction Michael Karamouzis, Papagou/GR and Massimo di Maio, Naples/IT

14.50 Presenting bad news to the patient Francesco Atzori, Cagliori/IT

15.05 The risk of burn out: Are young oncologists at higher risk? Christophe Massard, Villejuif/FR

15.20 Presenting a completed research project as an oral presentation

Valentina Guarneri, Modena/IT

15.35 Presenting the data of a project in a manuscript Evandro De Azambuja, Brussels/BE

15.50 Discussant Valter Torri, Milan/IT

16.00 Michael Karamouzis, Papagou/GR and Massimo di Maio, Naples/IT

15.30–17.00Educational session Soft tissue sarcoma: From molecular diagnosisto selection of treatmentChair: Ian Judson, Sutton/GBCo-Chair: Serge Leyvraz, Lausanne/CH

15.30 Pathologic diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies

Eva Wardelmann, Bonn/DE

16.00 Histology-driven chemotherapy of soft tissue sarcoma Mikael Eriksson, Lund/SE 16.30 Targeted therapies in soft tissue sarcoma Ian Judson, Sutton/GB 15.30–17.00Educational sessionDiagnostic and management issuesin gastroesophageal cancerChair: Florian Lordick, Heidelberg/DECo-Chair: João Oliveira, Lisbon/PT

15.30 Is there any role for surgery in the multidisciplinary treatment of esophageal cancer?

Michael Stahl, Essen/DE

16.00 Multimodality treatment for localized gastroesophageal cancer David Cunningham, Sutton/GB

16.30 New trends for staging and therapy for localized gastroesophageal cancer: The role of PET scan

Florian Lordick, Heidelberg/DE

15.30–17.00Special symposiumToxicities of targeted therapies: Prevention and managementChair: Fausto Roila, Terni/ITCo-Chair: Dorothy M.K. Keefe, Adelaide/AU

15.30 Introduction Dorothy M.K. Keefe, Adelaide/AU

15.35 Skin toxicity Mario Lacouture, Chicago, IL/US

16.00 Gastrointestinal toxicity Dorothy M.K. Keefe, Adelaide/AU

16.25 Renovascular and cardiac toxicity Thomas Suter, Bern/CH 16.50 Conclusions Fausto Roila, Terni/IT 16.30–17.30Controversy sessionActive surveillance in early prognosis prostatecancer should be standard of care Moderator: Sten Nilsson, Stockholm/SE

16.30 Introduction and vote Sten Nilsson, Stockholm/SE



Milan 2010

16.40 Pro speaker Fritz Schröder, Rotterdam/NL

17.00 Contra speaker Kurt Miller, Berlin/DE

17.20 Conclusions and vote Sten Nilsson, Stockholm/SE

Monday, 11 October 2010

07.45–08.45Highlights of the Day 1

08.00–08.45Young Oncologist BreakfastMedical information: Where to find it, what to trustLewis Rowett, Oxford/GB

08.00–09.00Challenge Your Expert sessionNasopharyngeal cancer Anthony Chan, Hong Kong/CN

08.00–09.00Challenge Your Expert sessionAdvances of systemic treatment in metastatic melanomaAlexander M.M. Eggermont, Rotterdam/NL 08.00–09.00Challenge Your Expert sessionMultiple myeloma Joan Bladé, Barcelona/ES

08.00–09.00Challenge Your Expert sessionAdvances in the treatment of metastaticor unresectable biliary tract cancerJuan W. Valle, Manchester/GB

08.00–09.00Patient cases sessionEarly endometrial cancer Chairs and Speakers: Carien L. Creuzberg, Leiden/NLand Thomas Högberg, Lund/SE

08.00 Chemotherapy Thomas Högberg, Lund/SE

08.10 Radiotherapy Carien L. Creuzberg, Leiden/NL

08.20 Discussion

08.00–09.00Patient cases sessionGenotyping GIST for clinical decision-makingChairs and Speakers: Alessandro Gronchi, Milan/IT and Peter Reichardt, Bad Saarow/DE

08.00 Tailoring the drug Peter Reichardt, Bad Saarow/DE

08.10 Tailoring the scalpel Alessandro Gronchi, Milan/IT

08.20 Discussion

09.00–10.30Special symposiumBreast cancer challenges in the setting of curable diseaseChair: Wolfgang Eiermann, Munich/DE andSabino De Placido, Naples/IT

09.00 Introduction Sabino De Placido, Naples/IT

09.05 Preservation of fertility in young patients Kutluk Oktay, New York, NY/US

09.25 Optimizing endocrine treatment of pre-menopausal women

Mitchell Dowsett, London/GB

09.45 Should bone-targeting therapy be used in the adjuvant setting? Robert Coleman, Sheffield/GB

10.05 Evolving issues in inflammatory breast cancer Luca Gianni, Milan/IT

10.25 Conclusions Wolfgang Eiermann, Munich/DE 09.15–10.15Controversy sessionMaintenance treatment of advanced NSCLC:Utopia or necessity? Moderator: Robert Pirker, Vienna/AT

09.15 Introduction and vote Robert Pirker, Vienna/AT

09.25 Speaker for Necessity Maurice Perol, Lyon/FR

09.45 Speaker for Utopia Giorgio Scagliotti, Orbassano/IT

10.05 Conclusions and vote Robert Pirker, Vienna/AT 09.15–10.15Multidisciplinary Interactive Session (MIS)Localised prostate cancer Chairs and Speakers: Alan Horwich, Sutton/GB andRobert A. Huddart, Sutton/GB

09.15 Alan Horwich, Sutton/GB

09.30 Robert Huddart, Sutton/GB

09.45 Discussion



Milan 2010

09.15–10.45Young Oncologists ForumSupportive care of cancer patientsChairs: Michael Karamouzis, Papagou/GRCo-Chair: Serena Di Cosimo, Barcelona/ESSession shooters: Evandro De Azambuja, Brussels/BE;Gilberto de Castro Junior, São Paolo/BR;Margaret Hutka, Gliwice/PL; Pia Osterlund, Helsinki/FI

09.15 Introduction Michael Karamouzis, Papagou/GR

09.20 Management of cancer pain Julia Riley, London/GB

09.40 Systemic therapeutic options for bone metastases Tiina Saarto, Helsinki/FI

10.00 Management of fatigue/cachexia Stein Kaasa, Trondheim/NO

10.20 Palliative chemotherapy versus best palliative care – evidence based decisions Jean-Philippe Durand, Paris/FR

10.40 Conclusions Serena Di Cosimo, Barcelona/ES 10.45–12.15Special symposiumMicroRNA’s: The new genes involved in cancerChair: Carlo Croce, Columbus, OH/USCo-Chair: Ruggero De Maria, Rome/IT

10.45 Introduction Ruggero De Maria, Rome/IT

10.50 MicroRNA identification in plasma and serum: A new tool to diagnose and monitor diseases George Calin, Houston, TX/US

11.10 Micromanagers of malignancy:The role of microRNAs in regulating metastasis Carlo Croce, Columbus, OH/US

11.30 miRNA in lymphomas, profile expression/prognosis Charles Lawrie, Oxford/GB

11.50 MicroRNAs are involved in tumor migration and invasion Reuven Agami, Amsterdam/NL

12.10 Conclusions Ruggero De Maria, Rome/IT 10.45–12.15ESMO/ASCO Joint SymposiumThe future of antiangiogenesis therapy Chairs: David J. Kerr, Oxford/GB & Doha/QA andGeorge Sledge, Indianapolis, IN/US

10.45 Introduction George Sledge, Indianapolis, IN/US

10.55 The biology of antiangiogenic therapy in the adjuvant setting Peter Carmeliet, Leuven/BE

11.15 Preclinical biology as it relates to adjuvant therapy Bob Kerbel, Toronto/CA

11.35 An analysis of currently available adjuvant colorectal data Lee M. Ellis, Houston, TX/US

11.55 COX-2 inhibition in the adjuvant setting for colorectal cancer: Antiangiogenic effect? David J. Kerr, Oxford/GB & Doha/QA 10.45–12.15Oncology mentors ForumCo-Chairs: Heine H. Hansen, Copenhagen/DK andMartin Gore, London/GB

10.45 Introduction TBC

10.50 Global recognition of medical oncology Eduardo Cazap, Buenos Aires/AR 11.00 ESMO/ASCO updated Global Core Curriculum for

training in medical oncology and log book opportunities Heine H. Hansen, Copenhagen/DK

11.20 How you and your institution can benefit from being a home or host mentor within the ESMO fellowship program

Martin Gore, London/GB

11.35 How to check the status of your trainees knowledge and readiness for the license exam:

ESMO examination opportunities Carsten Bokemeyer, Hamburg/DE 11.50 Teaching medical oncology to medical students Nicholas Pavlidis, Ioannina/GR

12.05 Q&A Heine H. Hansen, Copenhagen/DK and Martin Gore, London/GB 11.00–12.30Special symposiumOvercoming disparities in cancer control in EuropeChair: Hans H. Storm, Copenhagen/DKCo-Chair: Hans-Jörg Senn, St. Gallen/CH

11.00 Introduction Hans-Jörg Senn, St. Gallen/CH

11.05 Differences in cancer survival in Europe Franco Berrino, Milan/IT

11.25 Social inequalities and cancer Anton Kunst, Amsterdam/NL

11.45 Cancer control plans in Europe Andreas Ullrich, Geneva/CH 12.05 Moving forward with cancer control Nick Fahy, Luxembourg/LU

12.25 Conclusions Hans H. Storm, Copenhagen/DK



Milan 2010

12.30–13.20Keynote lectureDetection, clinical relevance and specific biologicalproperties of disseminated cancer cells Chair: Carlos Caldas, Cambridge/GB Keynote Speaker: Klaus Pantel, Hamburg/DE 13.30–15.00Awards session

13.45–15.15Special symposiumOvarian cancer: New biology, new targetsChair: Stan Kaye, Sutton/GBCo-Chair: David Huntsman, Vancouver/CA

13.45 Introduction Stan Kaye, Sutton/GB

13.50 Molecular classification of ovarian cancer David Bowtell, Melbourne/AU

14.10 Ovarian cancer: The new pathology David Huntsman, Vancouver/CA

14.30 Pathway driven treatments of ovarian cancer: Beyond chemotherapy Cristiana Sessa, Bellinzona/CH

14.50 Functional imaging of ovarian cancer Elisabeth De Vries, Groningen/NL

15.10 Conclusions Stan Kaye, Sutton/GB

15.15–17.30Presidential Symposium

15.30–17.00Special symposiumTailoring treatment of metastatic colorectal cancer Chair: Jean-Yves Douillard, St-Herblain/FRCo-Chair: Eduardo Diaz-Rubio, Madrid/ES

15.30 Introduction Eduardo Diaz-Rubio, Madrid/ES

15.35 Aggressive versus non-aggressive initial treatment Tim Maughan, Cardiff/GB

15.55 Intermittent or continuous therapy Cornelis Punt, Nijmegen/NL

16.15 Personalizing treatment based on biomarkers Sabine Tejpar, Leuven/BE 16.35 The combination of targeted agents: A look to the future Arnaud Roth, Geneva/CH

16.55 Conclusions Jean-Yves Douillard, St-Herblain/FR

15.30–17.00Special symposiumTargeted agents in prostate cancer:Changing the paradigmsChair: Thomas Powles, London/GBCo-Chair: Karim Fizazi, Villejuif/FR

15.30 Introduction Karim Fizazi, Villejuif/FR

15.35 Improved inhibition of the androgen receptor Gerhardt Attard, Sutton/GB

15.55 Angiogenesis in prostate cancer Kevin Kelly, New Haven, CT/US

16.15 Bone targeting in prostate cancer Karim Fizazi, Villejuif/FR

16.35 Results from molecular biology that translate to treatment

Jack Schalken, Nijmegen/NL

16.55 Conclusions Thomas Powles, London/GB

Tuesday, 12 October 2010

07.45–08.00Highlights of the Day 2

08.00–09.00Challenge Your Expert session (repetition)Nasopharyngeal cancer 08.00–09.00Challenge Your Expert session (repetition)Advances of systemic treatment in metastatic melanoma 08.00–09.00Challenge Your Expert session (repetition)Multiple myeloma

08.00–09.00Challenge Your Expert session (repetition)Advances in the treatment of metastatic orunresectable biliary tract cancer

08.00–09.00Patient cases sessionDiagnosis and management of transformation Chairs and Speakers: Gianluca Gaidano, Novara/ITand Silvia Montoto, London/GB

08.00 Richter's syndrome Gianluca Gaidano, Novara/IT

08.10 Transformed follicular lymphoma Silvia Montoto, London/GB

08.20 Discussion



Milan 2010

08.00–09.00Patient cases sessionApproaches to adjuvant treatment of small tumorsChairs and Speakers: Raimund Jakesz, Vienna/AT andEric Winer, Boston, MA/US

08.00 The risk of stage and the risk of tumor biology: Microscopic nodal tumor

Raimund Jakesz, Vienna/AT

08.10 Triple negative small tumors Eric Winer, Boston, MA/US

08.20 Discussion 09.00–10.30Educational session (repetition)Towards an individualized approach of advancednon-small cell lung cancer

09.00–10.30Educational session (repetition)Soft tissue sarcoma: From molecular diagnosisto selection of treatment

09.15–10.45Special symposiumEmerging concepts in head and neck cancer diagnosticsand therapyChair: Fortunato Ciardiello, Naples/ITCo-Chair: Lisa Licitra, Milan/IT

09.15 Introduction Lisa Licitra, Milan/IT

09.20 Biomarkers in molecular classification and diagnostics of head and neck squamous cell carcinoma

Amanda Psyrri, Athens/GR

09.40 New signalling pathway inhibitors and EGFR resistance Fortunato Ciardiello, Naples/IT

10.00 Therapeutic implications of HPV positive tumors Maura Gillison, Columbus, OH/US

10.20 Molecularly-targeted therapies in thyroid cancer Jean-Pierre Droz, Lyon/FR

10.40 Conclusions Lisa Licitra, Milan/IT 09.15–10.15Controversy sessionAccess to novel drugs improves survivalModerator: Thomas Szucs, Basel/CH

09.15 Introduction and vote Thomas Szucs, Basel/CH

09.25 Pro Speaker Ivar Kristiansen, Oslo/NO

09.45 Contra Speaker Franz Porzsolt, Ulm/DE

10.05 Conclusions and vote Thomas Szucs, Basel/CH

09.15–10.15Multidisciplinary Interactive Session (MIS)Locally advanced laryngeal cancerChairs and Speakers: Guy Andry, Brussels/BE andJacques Bernier, Genolier/CH

09.15 Guy Andry, Brussels/BE

09.30 Jacques Bernier, Genolier/CH

09.45 Discussion 11.00–12.30Educational session (repetition)Diagnostic and management issues ingastroesophageal cancer 11.00–12.30Educational session (repetition)Advances in head and neck cancer

11.15–12.45Special symposiumThe use of biomarkers to guide treatment inhematological malignanciesChair: Martin Dreyling, Munich/DECo-Chair: Andreas Hochhaus, Jena/DE

11.15 Introduction Andreas Hochhaus, Jena/DE

11.20 Chronic lymphocytic leukemia Stephan Stilgenbauer, Ulm/DE

11.40 Multiple myeloma Michel Attal, Toulouse/FR

12.00 Mantle cell lymphoma Martin Dreyling, Munich/DE

12.20 Chronic myeloid leukemia Andreas Hochhaus, Jena/DE

12.40 Conclusions Martin Dreyling, Munich/DE

11.15–12.45ESMO DCTF/UICC/WHO Joint SymposiumMeeting the challenge of managing cervical cancerin the developing world Chair: Eduardo Cazap, Buenos Aires/ARCo-Chair: Andreas Ullrich, Geneva/CH

11.15 What is the optimal screening of cervical cancer in developing countries?

Rengaswamy Sankaranarayanan, Lyon/FR

11.35 HPV vaccination: What practical experience tells us to date

Vivien Tsu, Seattle, WA/US

11.55 Can we treat cervical cancer on a dollar a day? Mike Chirenje, Avondale/ZW

12.15 A Health Minister’s response to managing cervical cancer in low-income countries

Carlos Vallejos-Sologuren, Lima/PE

12.35 Conclusions Adamos Adamou, Nicosia/CY


congress

Milan 2010

Saturday, 9 October 2010

15.00–15.10Opening session and welcomeChairs: Lorenz Jost, Bruderholz/ CH andFrancesco De Lorenzo, Rome/IT 15.10–16.40Cancer: We all care and shareChairs: Francesco De Lorenzo, Rome/IT and TBC

15.10 The status of cancer in Europe now Andrea Micheli, Milan/IT

15.25 What the European Union can do for patients Alojz Peterle, Brussels/BE

15.40 What cancer advocacy groups can do for patients Jan Geissler, Riemerling/DE

15.55 General discussion

16.40–17.10Coffee break

17.10–18.40Understanding new methods and new treatments of cancerChairs: Elisabetta Iannelli, Rome/IT and Roberto Labianca, Bergamo/IT

17.10 Targeted therapy: A general overview Manfred Kaufmann, Frankfurt/DE

17.30 My life with targeted therapy Elisabetta Iannelli, Rome/IT

17.40 Targeted therapy: Hope or hype Jean-Charles Soria, Villejuif/FR

18.00 Participation in phase I studies Silvia Marsoni, Milan/IT


VenueThe 8th ESMO Patient Seminar will be held at the venue of the 35th ESMO Congress, the Fiera Milano Congressi, Milan, Italy.

LanguagesThe lectures will be given in English and Italian, with simultaneous translation into each language.

ESMO is pleased to announce that the 8th Patient Seminar will be held on Saturday 9 and Sunday 10 October 2010during the 35th ESMO Congress, Milan 2010.

RegistrationOnline registration will be available from Spring 2010 at www.esmomilan2010.org

Travel grantsLimited financial support to facilitate participation by interested patients and family members will be available from ESMO upon application.

'Born again', 2006 Images of Hope winning photo

8th ESMO Patient Seminar


congress

Milan 2010

Sunday, 10 October 2010

09.30–10.30Living with cancer: Early rehabilitationChairs: Stella Kyriakides, Nicosia/CY andPaola Varese, Ovada/IT

09.30 Why we need early rehabilitation Anita Margulies, Zurich/CH

09.45 The importance of psycho-oncology Luigi Grassi, Ferrara/IT 10.00 Common paths in the European Union Sanja Rozman, Ljubljana/SI

10.15 General Discussion

09.30–09.45Why we need early rehabilitation Anita Marguiles, Zurich/CH

09.45 The importance of psycho-oncology Luigi Grassi, Ferrara/IT 10.00 Common paths in the European Union Sanja Rozman, Ljubljana/SI


10.30–10.45Break

10.45–12.15Living with cancer: Long-term rehabilitationChairs: Elisabetta Iannelli, Rome/IT andDorothy M.K. Keefe, Adelaide/AU

10.45 The long term and late effects of cancer: Implications for research and public policy Kevin Stein, Atlanta, GA/US

11.15 Psychological and social consequences Patrizia Pugliese, Rome/IT

11.30 Poster presentation and discussion

12.15–13.15Lunch

13.15–14.15Do we always need specific cancer treatment? Chairs: Stella Kyriakides, Nicosia/CY andKevin Stein, Atlanta/US

13.15 General principles in treatment of frail and elderly patients Matti Aapro, Genolier/CH

13.30 What is co-morbidity and how is it evaluated? Dirk Schrijvers, Antwerp/BE

13.45 When not to operate Alberto Costa, Milan/IT


14.30–15.30Breakout sessionLatest developments in breast cancer

14.30 Overview & Presentation: Latest developments in breast cancer TBC

14.45 General discussion: Latest developments in breast cancer

14.30–15.30Breakout sessionLatest developments in gastrointestinal tumors Chair: Jim Cassidy, Glasgow/GB and TBC

14.30 Overview & Presentation: Latest developments in gastrointestinal tumors Jim Cassidy, Glasgow/GB

14.45 General discussion: Latest developments in gastrointestinal tumors

14.30–15.30Breakout sessionLatest developments in hematological malignancies Chairs: Michaeal Hallek, Cologne/DE andDavide Petruzzelli, Brugherio/IT

14.30 Overview & Presentation: Latest developments in hematological malignancies Michael Hallek, Cologne/DE

14.45 General discussion: Latest developments in hematological malignancies

14.30–15.30Breakout sessionLatest developments in prostate cancerChairs: Francesco Montorsi and Milan/IT andRiccardo Valdagni, Milan/IT

14.30 Overview & Presentation: Latest developments in prostate cancer Francesco Montorsi, Milan/IT

14.45 General discussion: Latest developments in prostate cancer

15.40–16.40Review and general discussionChairs: Lorenz Jost, Bruderholz/ CH and TBCPanel: TBC

15.40 Short review of major points emerging from the breakout sessions


8th ESMO Patient Seminar


congress

Milan 2010

Pre-registration closureOn 2 September 2010 the pre-registration period will be closed and new registrations will only be possible at the on-site registration fee.

Payment proceduresPayment must accompany each registration and be proc-essed within the appropriate deadline by:

• Credit card Visa or Euro/MasterCard only (please note that American

Express and Diners are not accepted)

• Bank transfer Applicable to registrations by fax only. Please see the

registration from for payment details.

• Bank Draft Made payable toEuropean Society for Medical Oncology - ESMO

Please note that neither personal cheques nor Eurocheques are accepted.

For countries where financial transfers are particularly difficult, please contact the ESMO Congress Department. Pre-registration can be accepted without pre-payment if accompanied by a letter of justification. Payment will then be settled on-site at the fee applicable at the date of receipt of the registration form and letter.

Cancellation refund policyRefund of the registration fee (minus e100 for adminis-tration costs) will be granted if notification of cancellation reaches the ESMO Congress Department in writing before 4 August 2010. After this date cancellations will not be refunded. Refunds by bank transfer or to a credit card will be processed after the Congress.

The 35th ESMO Congress registration fee includes only the following benefitsAccess to the Congress, Opening ceremony, Welcome reception, Industry Satellite symposia, concomitant trade Exhibition, public transportation between the hotels booked through the official housing agency and the Congress ven-ue, lunches on Saturday, Sunday and Monday. The fee also includes one copy each of the Abstract Book and Program Book. For ESMO members and non-ESMO members who elect to pay the additional Webcast fee, access rights to the Web-cast is also included.A limited number of Educational Books will be available on a first come, first served basis.Note: The Educational Books will be available online after the Congress.

Confirmation of registrationConfirmation of registration will be sent via E-mail to all pre-registered participants, approximately one month be-fore the start of the Congress. The confirmation is the only official document which certifies registration for the Con-gress and this document must be shown on-site in order to receive the Congress registration material (bag, books, badge, etc). Registration material may be collected from Thursday, 7 October 2010.

BadgeOnce the participant has received his/her badge, it is the only official evidence of registration. Please note that par-ticipants not wearing their badge do not have access to the Congress. Loss of badge is loss of registration and a new badge will only be issued upon payment of the fee on a pro-rata basis.

Important information for participants registered as part of a groupPlease note that if a participant is registered in the group registration procedure, the group leader may instruct the ESMO Congress Department to send the confirmations for each group member directly to the group leader and not to the individual participants. The leader may then collect the participants’ registration material on-site. Should the individual wish to collect his/her own material, he/she is kindly requested to contact their group leader. Registration material will only be given in exchange for the original con-firmation of registration in all cases.

Mailing listDuring the registration process participants may inform ESMO if they wish to be excluded from the general mailing list. The general mailing list will be made available to enti-ties other than ESMO (pharmaceutical companies, publish-ers, other scientific societies) for pre- and post-Congress mailings. Exclusion from the mailing list does not prevent the participant from receiving all ESMO related correspond-ence and announcements.

ExhibitorsOwners, representatives and employees of exhibiting firms will have the possibility to request an unlimited number of “Exhibitor” badges free of charge through the exhibitor’s manual and the online registration system.The “Exhibitor” badge authorizes access to the Exhibi-tion and Industry Satellite symposia but does not author-ize entrance to the scientific activities and functions of the Congress.

Exhibition visitorsExhibition visitors may register on-site at the fee of e60. The “Exhibition visitor” badge authorizes access to theExhibition only.

Registration


congress

Milan 2010

Registration

Italian VAT (20%) included Early registration feeuntil 7 July 2010

Late registration feeuntil 1 September 2010

On-site registration fee

from 2 September 2010

ESMO memberFee includes Webcast package 300 600 900

Junior ESMO memberFee includes Webcast package 60 60 60

Non-ESMO memberWebcast package INCLUDED

576 786 936

Non-ESMO memberWebcast package NOT INCLUDED 540 750 900

Discounted fee* 120 Not available Not available

Individuals

How to register• Online at the ESMO Website www.esmomilan2010.org

(credit card payment only)• Download and fax the registration form from the ESMO

Website registration section

Note: If you are an ESMO Member or already have a useraccount with ESMO, you may login to registration system with your user name and password.

For information or special requests, please contact:[email protected]

Registration feesThe ESMO Congress Department must receive one com-pleted registration form per participant and the correspond-ing payment in Euro by the deadlines given below. Please note that registration per day is neither possible through the pre-registration procedure nor on-site.

Congress Webcast: Access to the Congress Webcast will be restricted for the first 3 months following the Congress to ESMO members and non-ESMO members who elect to pay the additional Webcast fee; thereafter the Webcast will be freely available to everyone.

Groups

Group registration is available when the number of participants therein reaches a minimum of 10 individuals. Group instructions, terms and conditions are available on the ESMO Website via www.esmomilan2010.org.

Any questions regarding group registration may be addressed to [email protected]

Group registration deadlines

Payment of early fees, contingent without names 7 July 2010

Participant names to be received 4 August 2010

Late registration deadline and name changes at no charge until 1 September 2010

Collection of material on-site from 7 October 2010

*Applicable to ESMO members who are nurses and ESMO members from developing countries only. At the time of application, developingcountries are defined by ESMO according to latest World Bank statistics as countries with a Purchasing Power Parity (PPP) per capita of less than $10,000 per annum. Information available online at www.worldbank.org


congress

Milan 2010


congress

Milan 2010

Hotel accommodation for individual participants or groups with less than ten roomsPlease ensure your hotel reservation is made by 8 September 2010. After this date, room availability is not guaranteed.

A list of Congress hotels, terms and conditions of booking, a housing form as well as the online reservation system are now available on the Website: www.aimgroup.eu/2010/esmo.

A large number of rooms at preferential rates in different price categories have been reserved in Milan for the period of the Congress. The Congress venue, the Fiera Milano Congressi, is accessible by public transport.

Each reservation will be processed ONLY if accompanied by credit card details which are requested as a guarantee.

Payment informationA reservation fee of e20 (VAT 20% included) will be charged to the given credit card upon confirmation of the booking. Aim Group – AIM Dmc will issue an invoice for the charged reservation fee and a voucher will be sent out as confirmation.

The credit card will be kept as a guarantee for the hotel reservation but no further cost will be charged to it. The payment of the total foreseen will be requested by the hotel upon check-out.

The hotel will issue an invoice directly upon check out.

AIM Group – AIM Dmc will be at your disposal for any information about hotel reservations.

CancellationAny change or cancellation of the hotel reservation must be sent in writing to AIM Group - AIM Dmc (by regular E-mail or fax) according to the following conditions:

AIM Group - AIM Dmc reserves the right to charge the given credit card the following cancellation fees

Before 6 September 2010only the reservation fee (e20) will be charged

Before 30 September 2010one night’s accommodation will be charged

After 30 September 2010100% of the foreseen total number of nights will be charged

Hotel accommodation for groups(groups with 10 or more rooms)For group bookings, please contact AIM Group- AIM Dmc to obtain the “Terms and conditions for groups”.

On-site transportationPublic transportation is included in the registration fee for travel between the congress center and the official hotels booked through AIM Group-AIM Dmc.

Airport transfersAIM Group-AIM Dmc offers the possibility to organize transfers from and to the airport. For further information please contact AIM Group-AIM Dmc.

Optional ToursTours will be available only on the AIM Group-AIM Dmc Website.For further organizational matters AIM Group-AIM Dmc will be pleased to assist you.

AIM Group-AIM Dmc has been appointed by ESMO to manage hotel accommodation in relation to the 35th ESMO Congress.

Send fax

AIM Group-AIM Dmc Accommodation DivisionVia Ripamonti 129IT-20141 MilanItalyTel. +39 (0)2 5660 11Fax +39 (0)2 5660 9043

Send E-mail

[email protected]

Hotel accommodation


congress

Milan 2010

Upcoming Conferences

30 June – 3 July 2010

11th World Congress on Gastrointestinal CancerBarcelona, Spain

8–12 October 2010

35th ESMO CongressMilan, Italy

9–10 October 2010

8th ESMO Patient SeminarMilan, Italy

26–27 November 2010

ESMO Symposium on Cancer biology for cliniciansNice, France

24–26 February 2011

2rd European Multidisciplinary Conference on Thoracic OncologyLugano, Switzerland

24–26 February 2011

3rd International Conference on Innovative Approaches in Head & Neck OncologyBarcelona, Spain

4 March 2011

8th Advanced Ovarian Cancer ConferenceValencia, Spain

28–29 April 2011

ESMO Symposium on Metastases Barcelona, Spain

4–7 May 2011

3rd IMPAKT Breast Cancer ConferenceBrussels, Belgium

23–27 September 2011

16th ECCO – 36th ESMO Multidisciplinary Cancer CongressStockholm, Sweden

For more details about these events, please visit www.esmo.org/events.html


congress

Milan 2010

Organization and contacts

Congress coordinationGeneral informationPrivate meetingsRegistration

Scientific programAbstractsPatient SeminarTravel grants

SponsorshipIndustry SatellitesymposiaAdvertising

Media relations

Hotelaccommodation

Exhibitionmanagement

Alessia Mora

Chantal Cornu

Diana De Simone

Natascha Gugolz

Kate Kronig

Thomas Cavadini

Francesca Longo

Letizia Scarfò

Renato Mutton

Vanessa Pavinato

Mariarosaria Cavaliere

Alessandra Buzzo

Anna Pellifroni

Valentina Viotti

Bettina Kreiner

Andrea Etz

ESMO

Via Luigi Taddei 4

CH-6962 Viganello-Lugano

Switzerland

www.esmomilan2010.org

AIM Group- AIM Dmc

Via G. Ripamonti, 129

IT-20141 Milan, Italy

www.aimgroup.it

MAW- Medizinische

Ausstellungs- u.

Werbegesellschaft

Freyung 6

AT-1010 Vienna, Austria

Congress Department

Tel. +41 (0)91 973 19 26

Fax +41 (0)91 973 19 18

[email protected]

Congress Department

Tel +41 (0)91 973 19 16

Fax +41 (0)91 973 19 18

[email protected]

Marketing Department

Tel. +41 (0)91 973 19 90

Fax +41 (0)91 973 19 05

[email protected]

Communication Department

Tel. +41 (0)91 973 19 07

Fax +41 (0)91 973 19 93

[email protected]

Accommodation Division

Tel. +39 02 5660 11

Fax +39 02 5660 9043

[email protected]

Tel. +43 1 536 63 35 or 42

Fax +43 1 535 60 16

[email protected]

ESMO membership inquiries should be directed toESMO Head Office, Membership DepartmentTel. +41 (0)91 973 19 20 / Fax +41 (0)91 973 19 [email protected]

Content ESMO Congress DepartmentGraphic Concept Variante S.A.Printing Salvioni Arti Grafiche S.A.

© March 2010European Society for Medical Oncology

Printed in Switzerland

congress

Milan 2010

Abstract submission

Submission options Deadlines

Abstracts must be submitted online only via www.esmomilan2010.org 19 May 2010

Late-breaking abstracts by E-mail to [email protected] 25 August 2010

Basic science and translational researchBreast cancer, advancedBreast cancer, earlyChest tumorsColorectal cancerDevelopmental therapeutics Genitourinary tumorsGeriatric oncology

Gynecological cancerHead and neck cancerHealth services and public health Hematological malignanciesMelanoma Neuro-oncologyNew diagnosticsNeuroendocrine tumors and CUP

Palliative carePrevention and screeningPsycho-oncologySarcomaSupportive careUpper gastrointestinal tumorsMiscellaneous

Abstract submission categories

We encourage you to submit your abstract now, present your cutting-edge results to the community of oncology professionals and contribute to advancing the science of medical oncology.

congress - rete oncologica piemonte · congress advanced program milan 2010 advanced program 35th...

Documents